Senior Management

Learn More

Shane J. Schaffer, PharmD

Chairman, Chief Executive Officer


Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 20-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions at Pfizer, Novartis and Sanofi (including predecessor companies).


Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation and managed care & reimbursement strategy for numerous products.


Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.

Raul R. Silva, MD

Chief Science Officer


Raul R. Silva, MD is a Co-Founder of Cingulate Therapeutics and serves as CSO. He is a practicing child and adolescent psychiatrist who has served as Associate Professor and Vice Chairman of Child and Adolescent Psychiatry at New York University School of Medicine in New York City. Prior to that, he was the Executive Director of Rockland Children’s Psychiatric Center. He also served as the Deputy Director in the Division of Child and Adolescent Psychiatry at Bellevue Hospital Center, also in New York City.


Dr. Silva has authored/coauthored over 125 publications and presented at grand rounds and national meetings on over 120 occasions. He has been Principal Investigator and Co-Investigator for 21 research projects in his field.


Dr. Silva received his Doctor of Medicine degree from Ross University. He completed his fellowship in child and adolescent psychiatry at Columbia University’s St. Luke’s/Roosevelt Hospital Center where he became the director of service and residency training director. Dr. Silva completed a psychopharmacology research fellowship at New York University Medical Center. Dr. Silva is board certified in general, child and adolescent psychiatry.

Louis G. Van Horn, MBA, CPA

Chief Financial Officer


Louis G. Van Horn serves as CFO. Mr. Van Horn is a strategic finance leader whose business acumen is based over 35 years of experience as a strategic finance leader serving in executive leadership roles with a variety of industries including pharmaceuticals as well as Big 4 CPA experience.


Prior to Cingulate, Mr. Van Horn was Executive Vice President and Chief Financial Officer for eleven years with Store Financial Services, LLC. During his tenure he led the finance organization, while also at points serving as chief operating officer and on the board of directors. Prior to Store Financial, he was Vice President & Comptroller (Chief Accounting Officer) for Kansas City Southern, a NYSE company,  for sixteen years. Earlier in his career, he worked in finance and accounting roles with Shell Oil Company, Yellow Freight Systems and PricewaterhouseCoopers. Mr. Van Horn has extensive corporate and not-for-profit board experience and was recognized by the Kansas City Business Journal as Chief Financial Officer of the Year in 2012.


Mr. Van Horn holds a Master’s degree in Business Administration, with distinction, from the Bloch School of Business at the University of Missouri – Kansas City and a Bachelor’s degree in Accounting from Westminster College in Fulton, Missouri. He is a Certified Public Accountant, a member of the Institute of Certified Public Accountants and Financial Executives International.

Craig S. Gilgallon, Esq.

General Counsel


Craig S. Gilgallon is a Co-Founder of Cingulate Therapeutics and serves as General Counsel.  As general counsel, he directs and manages all aspects of the company’s legal needs and corporate governance.  Concurrently, Craig S. Gilgallon is one of the founding members and partner of Pawar Gilgallon & Rudy, LLC, a full-service business practice where he is dedicated to the efficient handling of transactional matters.


Mr. Gilgallon has more than ten years of experience in transactional and corporate law. He has advised and represented clients from mid-sized and early stage to larger multi-nationals in many type and size transactions, including mergers, acquisitions, divestitures, corporate recapitalizations, restructurings and reorganizations; alternative entities (partnerships, limited liability companies, business trusts, etc.); joint ventures and employment, licensing and other corporate arrangements; private and public placements of debt and equity securities; private equity investments; initial public offerings; domestic tax-advantaged transactions; project finance; etc.


Mr. Gilgallon received a B.A. from Ithaca College and received his Juris Doctorate from the Thomas Jefferson School of Law.

Craig S. Tashjy

Vice President of Business Development and Investor Relations


Craig S. Tashjy is a Co-Founder of Cingulate Therapeutics and serves as the Vice President of Business Development and Investor Relations. Mr. Tashjy brings 20 years of experience as a financial professional to his work with Cingulate’s CEO, Management and Strategic Partners to identify and engage key relationships for product development, manufacturing and private equity investment.


Prior, Mr. Tashjy developed multi-platform distribution channels for both domestic and international financial service firms including Morgan Stanley Dean Witter, First Union Brokerage Services and Minnesota Life/Securian Financial Group. Most recently, he led a cross-functional team responsible for a distribution platform with sales in excess of $500M for Old Mutual.


Mr. Tashjy is a graduate of University of Maryland at College Park, attended Whittier Law School and maintains FINRA licensing.